List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1403 studies with search of: kidney cancer
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer
Conditions: Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Intervention: Drug: LBH589 (Panobinostat) and RAD001 (Everolimus)
2 Recruiting Follow-Up Study of Kidney Cancer Patients
Conditions: Kidney Cancer;   Renal Cell Cancer
Intervention:
3 Not yet recruiting Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer
Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib and Dalteparin mono and combination therapy
4 Recruiting Ixabepilone in Treating Patients With Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Intervention: Drug: ixabepilone
5 Active, not recruiting Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant interferon alfa
6 Recruiting Kidney Cancer in Caucasians and African Americans in the United States
Condition: Kidney Cancer
Interventions: Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Other: survey administration;   Procedure: evaluation of cancer risk factors;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
7 Terminated Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-Metastatic Kidney Cancer
Conditions: Kidney Cancer;   Renal Cell Carcinoma
Intervention: Biological: HSPPC-96
8 Completed Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride
9 Recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Stage IV Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine;   Biological: therapeutic autologous dendritic cells
10 Completed ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
Condition: Kidney Cancer
Intervention: Drug: gefitinib
11 Active, not recruiting Vaccine Therapy Combined With Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Biological: recombinant interferon alfa;   Biological: therapeutic autologous dendritic cells
12 Active, not recruiting High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
Condition: Kidney Cancer
Intervention: Biological: aldesleukin
13 Not yet recruiting Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
Condition: Advanced Renal Cell Carcinoma
Intervention:
14 Recruiting Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Bevacizumab
15 Recruiting Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
Conditions: Renal Cancer;   Kidney Cancer
Interventions: Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
16 Recruiting Autoantibody Blood Test in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method
17 Completed Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Procedure: laparoscopic surgery;   Procedure: radiofrequency ablation;   Procedure: thermal ablation therapy
18 Completed Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
19 Active, not recruiting Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Condition: Kidney Cancer
Interventions: Biological: alemtuzumab;   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
20 Recruiting Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services